FAKTOR-OPTIONSSCHEIN - JAZZ PHARMACEUTICALS Share Price

Certificat

DE000MG35286

Market Closed - Börse Stuttgart 09:18:54 24/05/2024 pm IST
9.17 EUR +0.88% Intraday chart for FAKTOR-OPTIONSSCHEIN - JAZZ PHARMACEUTICALS
Current month-13.25%
Date Price Change
24/24/24 9.17 +0.88%
23/24/23 9.09 -4.21%
22/24/22 9.49 -0.94%
21/24/21 9.58 -2.04%
20/24/20 9.78 -0.51%

Delayed Quote Börse Stuttgart

Last update May 24, 2024 at 09:18 pm IST

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying JAZZ PHARMACEUTICALS PLC
Issuer Morgan Stanley
WKN MG3528
ISINDE000MG35286
Date issued 26/04/2024
Strike 51.98 $
Maturity Unlimited
Parity 5.33 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 10.89
Lowest since issue 8.98
Spread 0.06
Spread %0.64%

Company Profile

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
Sector
-
More about the company

Ratings for Jazz Pharmaceuticals plc

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Jazz Pharmaceuticals plc

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
106.1 USD
Average target price
180.9 USD
Spread / Average Target
+70.55%
Consensus